Loading…
Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: An updated network meta-analysis
[Display omitted] •Induction chemotherapy (IC) is usually administered in locally advanced NPC.•Different IC regimens have been used but the best choice is still debatable.•Platinum-based doublet IC appears to have a benefit on overall survival.•The docetaxel-platinum-5-FU regimen improves local dis...
Saved in:
| Published in: | Critical reviews in oncology/hematology 2021-04, Vol.160, p.103244-103244, Article 103244 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c374t-e67bd5bee70ba147350cadc413206bd78c4de4414bd79b6dbffb30859dc6603c3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c374t-e67bd5bee70ba147350cadc413206bd78c4de4414bd79b6dbffb30859dc6603c3 |
| container_end_page | 103244 |
| container_issue | |
| container_start_page | 103244 |
| container_title | Critical reviews in oncology/hematology |
| container_volume | 160 |
| creator | Bongiovanni, Alberto Vagheggini, Alessandro Fausti, Valentina Mercatali, Laura Calpona, Sebastiano Di Menna, Giandomenico Miserocchi, Giacomo Ibrahim, Toni |
| description | [Display omitted]
•Induction chemotherapy (IC) is usually administered in locally advanced NPC.•Different IC regimens have been used but the best choice is still debatable.•Platinum-based doublet IC appears to have a benefit on overall survival.•The docetaxel-platinum-5-FU regimen improves local disease control.
Induction chemotherapy (IC) added to concurrent chemoradiotherapy (CCRT) appears to be superior to CCRT alone for locally-advanced nasopharyngeal carcinoma (NPC). The main objective of this network meta-analysis (NMA) was to assess the impact of different IC regimens on patient outcome.
We systematically searched and extracted data from randomized, controlled trials involving stage III-IV NPC patients randomly assigned to receive IC + CCRT vs. CCRT alone. Overall survival (OS), locoregional recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) in the two arms were compared using hazard ratios (HRs).
Eight clinical trials were identified including 2362 patients. OS-benefit from doublet IC regimens, in particular platinum-docetaxel and platinum-gemcitabine regimens, was seen. With regard to LRFS, docetaxel-platinum-5FU regimen showed a greater impact than the others. An indirect comparison between taxane- and gemcitabine-based IC regimens showed a benefit of the latter in terms of OS and DMFS.
Although CCRT with cisplatin has been the gold standard of treatment in NPC for several years. Docetaxel + cisplatin-IC and cisplatin + gemcitabine-IC regimens have a positive impact on survival in locally-advanced NPC and should be considered the new standard option. |
| doi_str_mv | 10.1016/j.critrevonc.2021.103244 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2489605239</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1040842821000329</els_id><sourcerecordid>2489605239</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-e67bd5bee70ba147350cadc413206bd78c4de4414bd79b6dbffb30859dc6603c3</originalsourceid><addsrcrecordid>eNqFkE1v1DAQQC0EoqXwF5CPXLL1V5yEW6mAVqrEBc6WM55lvSR2sJ1W--9xlVKOnGY082ZG8wihnO044_ryuIPkS8L7GGAnmOC1LIVSL8g577uhYUrzlzVnijW9Ev0ZeZPzkTGmlO5ekzMp214INZyTh9vgVig-BgoHnGM5YLLLiS7TminU9XH2xYaydZN1_hnxgQab43Kw6RR-op0o2AQ-xNl-pFeBrouzBR0NWB5i-kVnLLaxwU6n7PNb8mpvp4zvnuIF-fHl8_frm-bu29fb66u7BmSnSoO6G107InZstFx1smVgHSguBdOj63pQDpXiqubDqN2434-S9e3gQGsmQV6QD9veJcXfK-ZiZp8Bp8kGjGs2QvWDZq2QQ0X7DYUUc064N0vyc33OcGYetZuj-afdPGo3m_Y6-v7pyjrO6J4H_3quwKcNwPrrvcdkMngMgM4nhGJc9P-_8gf3xJ0S</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2489605239</pqid></control><display><type>article</type><title>Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: An updated network meta-analysis</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Bongiovanni, Alberto ; Vagheggini, Alessandro ; Fausti, Valentina ; Mercatali, Laura ; Calpona, Sebastiano ; Di Menna, Giandomenico ; Miserocchi, Giacomo ; Ibrahim, Toni</creator><creatorcontrib>Bongiovanni, Alberto ; Vagheggini, Alessandro ; Fausti, Valentina ; Mercatali, Laura ; Calpona, Sebastiano ; Di Menna, Giandomenico ; Miserocchi, Giacomo ; Ibrahim, Toni</creatorcontrib><description>[Display omitted]
•Induction chemotherapy (IC) is usually administered in locally advanced NPC.•Different IC regimens have been used but the best choice is still debatable.•Platinum-based doublet IC appears to have a benefit on overall survival.•The docetaxel-platinum-5-FU regimen improves local disease control.
Induction chemotherapy (IC) added to concurrent chemoradiotherapy (CCRT) appears to be superior to CCRT alone for locally-advanced nasopharyngeal carcinoma (NPC). The main objective of this network meta-analysis (NMA) was to assess the impact of different IC regimens on patient outcome.
We systematically searched and extracted data from randomized, controlled trials involving stage III-IV NPC patients randomly assigned to receive IC + CCRT vs. CCRT alone. Overall survival (OS), locoregional recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) in the two arms were compared using hazard ratios (HRs).
Eight clinical trials were identified including 2362 patients. OS-benefit from doublet IC regimens, in particular platinum-docetaxel and platinum-gemcitabine regimens, was seen. With regard to LRFS, docetaxel-platinum-5FU regimen showed a greater impact than the others. An indirect comparison between taxane- and gemcitabine-based IC regimens showed a benefit of the latter in terms of OS and DMFS.
Although CCRT with cisplatin has been the gold standard of treatment in NPC for several years. Docetaxel + cisplatin-IC and cisplatin + gemcitabine-IC regimens have a positive impact on survival in locally-advanced NPC and should be considered the new standard option.</description><identifier>ISSN: 1040-8428</identifier><identifier>EISSN: 1879-0461</identifier><identifier>DOI: 10.1016/j.critrevonc.2021.103244</identifier><identifier>PMID: 33582249</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Chemoradiotherapy ; Cisplatin ; Cisplatin - therapeutic use ; Docetaxel-cisplatin-5FU ; Gemcitabine ; Humans ; Induction Chemotherapy ; Nasopharyngeal carcinoma ; Nasopharyngeal Carcinoma - drug therapy ; Nasopharyngeal Neoplasms - drug therapy ; Network Meta-Analysis</subject><ispartof>Critical reviews in oncology/hematology, 2021-04, Vol.160, p.103244-103244, Article 103244</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-e67bd5bee70ba147350cadc413206bd78c4de4414bd79b6dbffb30859dc6603c3</citedby><cites>FETCH-LOGICAL-c374t-e67bd5bee70ba147350cadc413206bd78c4de4414bd79b6dbffb30859dc6603c3</cites><orcidid>0000-0003-0259-4167</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33582249$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bongiovanni, Alberto</creatorcontrib><creatorcontrib>Vagheggini, Alessandro</creatorcontrib><creatorcontrib>Fausti, Valentina</creatorcontrib><creatorcontrib>Mercatali, Laura</creatorcontrib><creatorcontrib>Calpona, Sebastiano</creatorcontrib><creatorcontrib>Di Menna, Giandomenico</creatorcontrib><creatorcontrib>Miserocchi, Giacomo</creatorcontrib><creatorcontrib>Ibrahim, Toni</creatorcontrib><title>Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: An updated network meta-analysis</title><title>Critical reviews in oncology/hematology</title><addtitle>Crit Rev Oncol Hematol</addtitle><description>[Display omitted]
•Induction chemotherapy (IC) is usually administered in locally advanced NPC.•Different IC regimens have been used but the best choice is still debatable.•Platinum-based doublet IC appears to have a benefit on overall survival.•The docetaxel-platinum-5-FU regimen improves local disease control.
Induction chemotherapy (IC) added to concurrent chemoradiotherapy (CCRT) appears to be superior to CCRT alone for locally-advanced nasopharyngeal carcinoma (NPC). The main objective of this network meta-analysis (NMA) was to assess the impact of different IC regimens on patient outcome.
We systematically searched and extracted data from randomized, controlled trials involving stage III-IV NPC patients randomly assigned to receive IC + CCRT vs. CCRT alone. Overall survival (OS), locoregional recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) in the two arms were compared using hazard ratios (HRs).
Eight clinical trials were identified including 2362 patients. OS-benefit from doublet IC regimens, in particular platinum-docetaxel and platinum-gemcitabine regimens, was seen. With regard to LRFS, docetaxel-platinum-5FU regimen showed a greater impact than the others. An indirect comparison between taxane- and gemcitabine-based IC regimens showed a benefit of the latter in terms of OS and DMFS.
Although CCRT with cisplatin has been the gold standard of treatment in NPC for several years. Docetaxel + cisplatin-IC and cisplatin + gemcitabine-IC regimens have a positive impact on survival in locally-advanced NPC and should be considered the new standard option.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Chemoradiotherapy</subject><subject>Cisplatin</subject><subject>Cisplatin - therapeutic use</subject><subject>Docetaxel-cisplatin-5FU</subject><subject>Gemcitabine</subject><subject>Humans</subject><subject>Induction Chemotherapy</subject><subject>Nasopharyngeal carcinoma</subject><subject>Nasopharyngeal Carcinoma - drug therapy</subject><subject>Nasopharyngeal Neoplasms - drug therapy</subject><subject>Network Meta-Analysis</subject><issn>1040-8428</issn><issn>1879-0461</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkE1v1DAQQC0EoqXwF5CPXLL1V5yEW6mAVqrEBc6WM55lvSR2sJ1W--9xlVKOnGY082ZG8wihnO044_ryuIPkS8L7GGAnmOC1LIVSL8g577uhYUrzlzVnijW9Ev0ZeZPzkTGmlO5ekzMp214INZyTh9vgVig-BgoHnGM5YLLLiS7TminU9XH2xYaydZN1_hnxgQab43Kw6RR-op0o2AQ-xNl-pFeBrouzBR0NWB5i-kVnLLaxwU6n7PNb8mpvp4zvnuIF-fHl8_frm-bu29fb66u7BmSnSoO6G107InZstFx1smVgHSguBdOj63pQDpXiqubDqN2434-S9e3gQGsmQV6QD9veJcXfK-ZiZp8Bp8kGjGs2QvWDZq2QQ0X7DYUUc064N0vyc33OcGYetZuj-afdPGo3m_Y6-v7pyjrO6J4H_3quwKcNwPrrvcdkMngMgM4nhGJc9P-_8gf3xJ0S</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Bongiovanni, Alberto</creator><creator>Vagheggini, Alessandro</creator><creator>Fausti, Valentina</creator><creator>Mercatali, Laura</creator><creator>Calpona, Sebastiano</creator><creator>Di Menna, Giandomenico</creator><creator>Miserocchi, Giacomo</creator><creator>Ibrahim, Toni</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0259-4167</orcidid></search><sort><creationdate>202104</creationdate><title>Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: An updated network meta-analysis</title><author>Bongiovanni, Alberto ; Vagheggini, Alessandro ; Fausti, Valentina ; Mercatali, Laura ; Calpona, Sebastiano ; Di Menna, Giandomenico ; Miserocchi, Giacomo ; Ibrahim, Toni</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-e67bd5bee70ba147350cadc413206bd78c4de4414bd79b6dbffb30859dc6603c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Chemoradiotherapy</topic><topic>Cisplatin</topic><topic>Cisplatin - therapeutic use</topic><topic>Docetaxel-cisplatin-5FU</topic><topic>Gemcitabine</topic><topic>Humans</topic><topic>Induction Chemotherapy</topic><topic>Nasopharyngeal carcinoma</topic><topic>Nasopharyngeal Carcinoma - drug therapy</topic><topic>Nasopharyngeal Neoplasms - drug therapy</topic><topic>Network Meta-Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bongiovanni, Alberto</creatorcontrib><creatorcontrib>Vagheggini, Alessandro</creatorcontrib><creatorcontrib>Fausti, Valentina</creatorcontrib><creatorcontrib>Mercatali, Laura</creatorcontrib><creatorcontrib>Calpona, Sebastiano</creatorcontrib><creatorcontrib>Di Menna, Giandomenico</creatorcontrib><creatorcontrib>Miserocchi, Giacomo</creatorcontrib><creatorcontrib>Ibrahim, Toni</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical reviews in oncology/hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bongiovanni, Alberto</au><au>Vagheggini, Alessandro</au><au>Fausti, Valentina</au><au>Mercatali, Laura</au><au>Calpona, Sebastiano</au><au>Di Menna, Giandomenico</au><au>Miserocchi, Giacomo</au><au>Ibrahim, Toni</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: An updated network meta-analysis</atitle><jtitle>Critical reviews in oncology/hematology</jtitle><addtitle>Crit Rev Oncol Hematol</addtitle><date>2021-04</date><risdate>2021</risdate><volume>160</volume><spage>103244</spage><epage>103244</epage><pages>103244-103244</pages><artnum>103244</artnum><issn>1040-8428</issn><eissn>1879-0461</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-1</notes><notes>ObjectType-Review-3</notes><notes>content type line 23</notes><abstract>[Display omitted]
•Induction chemotherapy (IC) is usually administered in locally advanced NPC.•Different IC regimens have been used but the best choice is still debatable.•Platinum-based doublet IC appears to have a benefit on overall survival.•The docetaxel-platinum-5-FU regimen improves local disease control.
Induction chemotherapy (IC) added to concurrent chemoradiotherapy (CCRT) appears to be superior to CCRT alone for locally-advanced nasopharyngeal carcinoma (NPC). The main objective of this network meta-analysis (NMA) was to assess the impact of different IC regimens on patient outcome.
We systematically searched and extracted data from randomized, controlled trials involving stage III-IV NPC patients randomly assigned to receive IC + CCRT vs. CCRT alone. Overall survival (OS), locoregional recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) in the two arms were compared using hazard ratios (HRs).
Eight clinical trials were identified including 2362 patients. OS-benefit from doublet IC regimens, in particular platinum-docetaxel and platinum-gemcitabine regimens, was seen. With regard to LRFS, docetaxel-platinum-5FU regimen showed a greater impact than the others. An indirect comparison between taxane- and gemcitabine-based IC regimens showed a benefit of the latter in terms of OS and DMFS.
Although CCRT with cisplatin has been the gold standard of treatment in NPC for several years. Docetaxel + cisplatin-IC and cisplatin + gemcitabine-IC regimens have a positive impact on survival in locally-advanced NPC and should be considered the new standard option.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33582249</pmid><doi>10.1016/j.critrevonc.2021.103244</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-0259-4167</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1040-8428 |
| ispartof | Critical reviews in oncology/hematology, 2021-04, Vol.160, p.103244-103244, Article 103244 |
| issn | 1040-8428 1879-0461 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2489605239 |
| source | ScienceDirect Freedom Collection 2022-2024 |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemoradiotherapy Cisplatin Cisplatin - therapeutic use Docetaxel-cisplatin-5FU Gemcitabine Humans Induction Chemotherapy Nasopharyngeal carcinoma Nasopharyngeal Carcinoma - drug therapy Nasopharyngeal Neoplasms - drug therapy Network Meta-Analysis |
| title | Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: An updated network meta-analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T15%3A35%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Induction%20chemotherapy%20plus%20concomitant%20chemoradiotherapy%20in%20nasopharyngeal%20carcinoma:%20An%20updated%20network%20meta-analysis&rft.jtitle=Critical%20reviews%20in%20oncology/hematology&rft.au=Bongiovanni,%20Alberto&rft.date=2021-04&rft.volume=160&rft.spage=103244&rft.epage=103244&rft.pages=103244-103244&rft.artnum=103244&rft.issn=1040-8428&rft.eissn=1879-0461&rft_id=info:doi/10.1016/j.critrevonc.2021.103244&rft_dat=%3Cproquest_cross%3E2489605239%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c374t-e67bd5bee70ba147350cadc413206bd78c4de4414bd79b6dbffb30859dc6603c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2489605239&rft_id=info:pmid/33582249&rfr_iscdi=true |